Literature DB >> 27078236

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Emily A Knapp1, Aliza K Fink1, Christopher H Goss2, Ase Sewall3, Josh Ostrenga1, Christopher Dowd1, Alexander Elbert1, Kristofer M Petren1, Bruce C Marshall1.   

Abstract

RATIONALE: The Cystic Fibrosis Foundation Patient Registry (CFFPR) is an ongoing patient registry study that collects longitudinal demographic, clinical, and treatment information about persons with cystic fibrosis (CF) in the United States. CF is a life-shortening genetic disorder that occurs in approximately 1 in 3,500 births in the United States. High-quality observational data is important for clinical research, quality improvement, and clinical management.
OBJECTIVES: To describe the data collection, patient population, and key limitations of the CFFPR.
METHODS: Inclusion criteria for the CFFPR include diagnosis with CF or a CFTR-associated disorder, care at an accredited care center program, and provision of informed consent. Data from clinic visits and hospitalizations are collected through a secure website. Loss to follow-up and generalizability were examined using several methods. The accuracy of CFFPR data was evaluated with an audit of 2012 CFFPR data compared to the medical record.
MEASUREMENTS AND MAIN RESULTS: Since 1986, the CFFPR contains the records of 48,463 individuals with CF. Participation among individuals seen at accredited care centers is high, and loss to follow-up is low. An audit of 2012 CFFPR data suggests that the CFFPR contains 95% of clinic visits and 90% of hospitalizations found in the medical record for these patients, and nearly all of the audited fields were highly accurate.
CONCLUSIONS: Registries such as the CFFPR are important tools for research, clinical care, and tracking incidence, mortality and population trends.

Entities:  

Keywords:  cystic fibrosis; registries

Mesh:

Year:  2016        PMID: 27078236     DOI: 10.1513/AnnalsATS.201511-781OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  112 in total

Review 1.  Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.

Authors:  Kathleen J Ramos; Ranjani Somayaji; David P Nichols; Christopher H Goss
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

2.  Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.

Authors:  Lisa B Feng; Scott D Grosse; Ridgely Fisk Green; Aliza K Fink; Gregory S Sawicki
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

3.  Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.

Authors:  Michael S Stalvey; Jesse Pace; Minoo Niknian; Mark N Higgins; Valerie Tarn; Joy Davis; Sonya L Heltshe; Steven M Rowe
Journal:  Pediatrics       Date:  2017-02       Impact factor: 7.124

4.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

5.  Pregnancy among cystic fibrosis women in the era of CFTR modulators.

Authors:  Sonya L Heltshe; Emily M Godfrey; Tatiana Josephy; Moira L Aitken; Jennifer L Taylor-Cousar
Journal:  J Cyst Fibros       Date:  2017-02-10       Impact factor: 5.482

6.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

7.  Predictive effects of low birth weight and small for gestational age status on respiratory and nutritional outcomes in cystic fibrosis.

Authors:  Samar E Atteih; Karen S Raraigh; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2020-02-12       Impact factor: 5.482

8.  Likelihood-based analysis of outcome-dependent sampling designs with longitudinal data.

Authors:  Leila R Zelnick; Jonathan S Schildcrout; Patrick J Heagerty
Journal:  Stat Med       Date:  2018-03-15       Impact factor: 2.373

Review 9.  The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease.

Authors:  Theodore G Liou
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

10.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.